Julie Chang

Julie Chang

Auto-generated profile, based on publicly available information

Julie Chang

Department of Bioengineering, Stanford University, Stanford, CA, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2019 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
JCJulie Chang
Julie Chang
OCOvijit Chaudhuri
Ovijit Chaudhuri
In epithelial cancers, cells must invade through basement membranes (BMs) to metastasize. The BM, a thin layer of extracellular matrix underlying epithelial and endothelial tissues, is primarily composed of laminin and collagen IV and serves as a structural barrier to cancer cell invasion, intravasation, and extravasation. BM invasion has been thought to require protease degradation since cells, which are typically on the order of 10 µm in size, are too large to squeeze through the nanometer-scale pores of the BM. However, recent studies point toward a more complex picture, with physical forces generated by cancer cells facilitating protease-independent BM invasion. Moreover, collective cell interactions, proliferation, cancer-associated fibroblasts, myoepithelial cells, and immune cells are all implicated in regulating BM invasion through physical forces. A comprehensive understanding of BM structure and mechanics and diverse modes of BM invasion may yield new strategies for blocking cancer progression and metastasis.

8 July 2019 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
RSRyan S. Stowers
Ryan S. Stowers
ASAnna Shcherbina
Anna Shcherbina
JIJohnny Israeli
Johnny Israeli
JGJoshua J. Gruber
Joshua J. Gruber
JCJulie Chang
Julie Chang
OCOvijit Chaudhuri
Ovijit Chaudhuri

5 December 2023 in Nature Medicine
Verified
Journal Article
Open access
PDF file
Jayesh DesaiJayesh Desai
Jayesh Desai
GAGuzman Alonso
Guzman Alonso
SKSe Hyun Kim
Se Hyun Kim
Andres CervantesAndres Cervantes
Andres Cervantes
TKThomas Karasic
Thomas Karasic
SHSae-Won Han
Sae-Won Han
KRAS G12C mutation is prevalent in ~4% of colorectal cancer (CRC) and is associated with poor prognosis. Divarasib, a KRAS G12C inhibitor, has shown modest activity as a single agent in KRAS G12C-positive CRC at 400 mg. Epidermal growth factor receptor has been recognized as a major upstream activator of RAS–MAPK signaling, a proposed key mechanism of resistance to KRAS G12C inhibition in CRC. Here, we report on divarasib plus cetuximab (epidermal growth factor receptor inhibitor) in patients with KRAS G12C-positive CRC (n = 29) from arm C of an ongoing phase 1b trial. The primary objective was to evaluate safety. Secondary objectives included preliminary antitumor activity. The safety profile of this combination was consistent with those of single-agent divarasib and cetuximab. Treatment-related adverse events led to divarasib dose reductions in four patients (13.8%); there were no treatment withdrawals. The objective response rate was 62.5% (95% confidence interval: 40.6%, 81.2%) in KRAS G12C inhibitor-naive patients (n = 24). The median duration of response was 6.9 months. The median progression-free survival was 8.1 months (95% confidence interval: 5.5, 12.3). As an exploratory objective, we observed a decline in KRAS G12C variant allele frequency associated with response and identified acquired genomic alterations at disease progression that may be associated with resistance. The manageable safety profile and encouraging antitumor activity of divarasib plus cetuximab support the further investigation of this combination in KRAS G12C-positive CRC.ClinicalTrials.gov identifier: NCT04449874

8 January 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
HLHong-Pyo Lee
Hong-Pyo Lee
FAFarid Alisafaei
Farid Alisafaei
KAKolade Adebawale
Kolade Adebawale
JCJulie Chang
Julie Chang
VSVivek B. Shenoy
Vivek B. Shenoy
OCOvijit Chaudhuri
Ovijit Chaudhuri
Cells utilize a nuclear piston to mechanically generate migration paths in confining matrices.

13 November 2023 in Nature Materials
Verified
Journal Article
Closed access
PDF file
JCJulie Chang
Julie Chang
ASAashrith Saraswathibhatla
Aashrith Saraswathibhatla
ZSZhaoqiang Song
Zhaoqiang Song
SVSushama Varma
Sushama Varma
CSColline Sanchez
Colline Sanchez
OCOvijit Chaudhuri
Ovijit Chaudhuri

1 August 2020 in Biophysical Journal
Verified
Journal Article
Closed access
JCJulie Chang
Julie Chang
EPEmily M. Pang
Emily M. Pang
KAKolade Adebowale
Kolade Adebowale
KWKatrina M. Wisdom
Katrina M. Wisdom
OCOvijit Chaudhuri
Ovijit Chaudhuri